Clinical Trials Logo

Clinical Trial Details — Status: Terminated

Administrative data

NCT number NCT02514733
Other study ID # STU00200153
Secondary ID
Status Terminated
Phase
First received
Last updated
Start date May 2016
Est. completion date April 2018

Study information

Verified date September 2018
Source Northwestern University
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a single center study that seeks to study the impact of donor age on recipient outcomes in older kidney transplant recipients.


Description:

Over the years use of older kidney allografts has increased in an attempt to bridge the gap between demand and supply of organs. Simultaneously there has been in increase in the number of elderly renal transplant recipients. Numerous factors, both graft and host related, can impact recipient outcomes. The aim of this study is to evaluate the impact of donor age on recipient outcomes, based on the hypothesis is that elderly recipients who receive an older allograft have poorer outcomes that those who receive a younger allograft.

Study subjects will be recruited from the cohort of patients who received a kidney transplant at Northwestern Memorial Hospital.

The transplant clinical database and electronic medical record (OTTR) used in the Comprehensive Transplant Center at Northwestern University will be scanned to screen for kidney transplant recipients who fit the inclusion and exclusion criteria. Potential subjects will then be consented to participate in the study (see attached consent form), and subject participation will be documented in OTTR.

The sample size for the study is 80 subjects, who will be divided into 2 groups based on recipient and donor age. All demographic and clinical data will be collected for the donor and recipients at time of transplant. Follow up clinical data, including but not limited to recipient survival and graft failure will be collected and analyzed for the recipients. Subject confidentiality will be strictly maintained. All subject data will be stored on a secure server and only shared between members of the research team. The investigators plan to publish the results in a peer reviewed journal.


Recruitment information / eligibility

Status Terminated
Enrollment 1
Est. completion date April 2018
Est. primary completion date April 2018
Accepts healthy volunteers No
Gender All
Age group 60 Years and older
Eligibility Inclusion Criteria:

- All adult kidney transplant recipients

- Recipient age > 60 years at the time of transplant

- Transplant was done between January 1, 2013 and December 31, 2014

Exclusion Criteria:

- Recipients of more than one kidney transplant

- Recipients of multi-organ transplants

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
United States Northwestern University Comprehensive Transplant Center Chicago Illinois

Sponsors (1)

Lead Sponsor Collaborator
Northwestern University

Country where clinical trial is conducted

United States, 

References & Publications (1)

Knoll GA. Kidney transplantation in the older adult. Am J Kidney Dis. 2013 May;61(5):790-7. doi: 10.1053/j.ajkd.2012.08.049. Epub 2012 Dec 20. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Graft failure Graft failure in this study is defined as need for chronic dialysis or re-transplant. 2 years post transplant
Secondary Recipient survival 2 years post transplant
See also
  Status Clinical Trial Phase
Completed NCT02014103 - Conversion From Brand to Generic Tacrolimus in High Risk Transplant Recipients Phase 4
Completed NCT02068872 - Gastric Sleeve Pilot Study in Morbidly Obese Undergoing Liver Transplantation Phase 1
Completed NCT02207322 - Supportive Care Intervention In Patients Hospitalized For Hematopoietic Stem Cell Transplantation (Shield) N/A
Active, not recruiting NCT02843321 - Combined Infusion of Cytotoxic T-Lymphocytes and Vaccination Phase 1
Completed NCT02800811 - Safety, Tolerability, PK, PD, and Immunogenicity of Single and Multiple Ascending Intravenous Doses of FR104 Phase 1